

EvaluatePharma®

Japan Sales, Volume and Pricing

With PMDA Approvals

Japan Sales, Volume and Pricing

Accelerate high quality analyses of the Japan market to optimise your business strategies through convenient access to Japan sales, volume and pricing and PMDA regulatory approval details; all fully integrated with EvaluatePharma global commercial intelligence.

Japan is the #2 pharmaceutical market in the world offering strong growth opportunities for internationally based companies and for local companies alike. Getting easy access to trustworthy Japan pricing and approvals data is very critical in order to achieve optimal launch price and product lifetime value. It allows you to readily conduct accurate commercial assessments and forecasting, understand the price premiums achieved for competitive products and compare international reference prices for negotiations.

Now Evaluate offers convenient access to superior quality Japan sales, volume, pricing and approvals data that can greatly enhance the efficiency and credibility of market analyses leading to faster, more effective decisions. This allows companies to focus on their plans rather than struggling with data.

Features

- Single source for Japanese MHLW pricing intelligence with PMDA approval information
- Accessible, translated NHI New Drug Pricing data set that makes it easy to access essential Japan pricing information for newly approved products on the Japan market, including:
 - Pricing premiums granted to a product(s) and on what basis prices were set
 - Company provided launch and peak sales forecasts and forecasted #patients
 - Fully transparent annual cost and volume per patient
 - Foreign price comparisons to US, Germany, UK and France - at time of launch
- NHI current drug prices for existing drugs on the Japan market with two year price revision history and analysis
- Dual language fields for company, product names and therapy class fields in Japanese and English integrated into Evaluate for in-depth analysis
- Direct links to full Japanese launch documents, no need for difficult searches or translation
- PMDA approvals information for all branded and generic products in Japan including in-depth label details and manufacturer information to aid assessments



Key Benefits:

- Unique commercial insight into the Japan market that saves massive amounts of time
- Convenience of conducting international drug price comparisons all in one resource
- Access to patient-based forecast models for similar products launched in Japan
- Transparency on new drug pricing methodology and premiums achieved for peer products
- Integration of pricing information with global commercial and R&D intelligence
- Translation to overcome language barriers and eliminate difficult document searches
- Competitive intelligence useful to various roles and functions for a shared view of the market



Population of over **127 million** people

2nd largest RX market worldwide: **US \$504.15 billion**

Soft patent erosion of off-patent branded products

Government reimbursement for drugs




Government sets prices;

adjustment every 2yrs

Getting the right price at launch is critical

\$ £ ¥ €





Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. We help our clients make high value decisions through superior quality, timely, must-have data and insights, combined with personalised, expert client support.

EvaluatePharma[®] delivers exclusive consensus sales forecasts and trusted commercial insight into biotech and pharmaceutical performance.

 [@EvaluatePharma](https://twitter.com/EvaluatePharma)

EvaluateMedTech[®] sets a new standard in commercial analysis and consensus forecasts of the global medical device and diagnostic industry.

 [@EvaluateMedTech](https://twitter.com/EvaluateMedTech)

EvaluateClinical Trials[®] delivers unique clinical trial intelligence expertly curated to efficiently analyse the global clinical trial landscape.

 [@EPClinicalTrial](https://twitter.com/EPClinicalTrial)

EP Vantage an award winning editorial team, provides daily commentary and analysis with fresh perspectives and insight into current and future industry trends.

 [@EPVantage](https://twitter.com/EPVantage)

Evaluate Custom Services provides customised solutions to help you access, analyse and manage the information you need to support effective decision-making.

The Evaluate services enable the life science community to make sound business decisions about value and opportunity.

www.evaluate.com

Evaluate Headquarters

Evaluate Ltd.
11-29 Fashion Street
London E1 6PX
United Kingdom
T +44 (0)20 7377 0800
F +44 (0)20 7539 1801

Evaluate Americas

EvaluatePharma USA Inc.
60 State Street, Suite 1910
Boston, MA 02109
USA
T +1 617 573 9450
F +1 617 573 9542

Evaluate Asia Pacific

Evaluate Japan KK
Akasaka Garden City 4F
4-15-1 Akasaka, Minato-ku
Tokyo 107-0052
Japan
T +81 (0)80 1164 4754